Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Significant Decline in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 54,947 shares, a decline of 74.3% from the December 15th total of 213,740 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average daily trading volume, of 162,551 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily trading volume, of 162,551 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.6% of the company’s shares are sold short.

Capstone Therapeutics Price Performance

Shares of CAPS stock opened at $0.63 on Wednesday. The stock has a 50 day moving average price of $0.83 and a 200 day moving average price of $1.14. Capstone Therapeutics has a 52-week low of $0.61 and a 52-week high of $4.18. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.35 and a current ratio of 0.95. The firm has a market capitalization of $5.24 million, a P/E ratio of -0.66 and a beta of -1.21.

Capstone Therapeutics (NASDAQ:CAPS) last released its earnings results on Tuesday, November 18th. The company reported ($0.35) earnings per share for the quarter. Capstone Therapeutics had a negative return on equity of 29.50% and a negative net margin of 12.40%.The business had revenue of $13.65 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. World Investment Advisors acquired a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned approximately 0.40% of Capstone Therapeutics as of its most recent SEC filing. Institutional investors own 2.55% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Capstone Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.